{"name":"X-pert Med GmbH","slug":"x-pert-med-gmbh","ticker":"","exchange":"","domain":"","description":"X-pert Med GmbH is a specialty pharmaceutical company focused on developing and commercializing innovative drug combinations. The company has two key products in its pipeline, including a marketed combination of Ibuprofen and Hydrocortisone, and a Phase 1 candidate combining Celecoxib and Ketoprofen.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ibuprofen, Hydrocortisone","genericName":"Ibuprofen, Hydrocortisone","slug":"ibuprofen-hydrocortisone","indication":"Inflammatory pain conditions","status":"marketed"}]}],"pipeline":[{"name":"Ibuprofen, Hydrocortisone","genericName":"Ibuprofen, Hydrocortisone","slug":"ibuprofen-hydrocortisone","phase":"marketed","mechanism":"Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, while hydrocortisone suppresses immune and inflammatory responses through glucocorticoid receptor activation.","indications":["Inflammatory pain conditions","Musculoskeletal inflammation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5DRm9BbnRUR2dSR0Jsa1hLZTFXY2JWc1NTN1JWR0tIZTYxUGVLUG5YNE5mTGpWQzB4T1BEakxvNERKbU5wZEMtVGgzd2E2eS00LVlacTJB?oc=5","date":"2024-06-21","type":"pipeline","source":"Xpert.Digital - Konrad Wolfenstein","summary":"The biotech or biopharma cluster in southern Germany based in Ulm is both a success story and a hidden champion at the same time - Xpert.Digital - Konrad Wolfenstein","headline":"The biotech or biopharma cluster in southern Germany based in Ulm is both a success story and a hidden champion at the s","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}